Seguridad de las vacunas Difteria- Tétanos - Pertussis acelular

1. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory committee (ACIP). MMWR Recomm Rep. 1991;40(RR-10):1–28

2. Cody CL, Baraff LJ, Cherry JD, Marcy SM, Manclark CR. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981;68(5):650–660

3. Long SS, Deforest A, Smith DG, Lazaro C, Wassilak GF. Longitudinal study of adverse reactions following diphtheriatetanus- pertussis vaccine in infancy. Pediatrics. 1990;85(3):294–302

4. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Morb Mortal Wkly Rep. 1997;46(30):706]. MMWR Recomm Rep. 1997;46(RR-7):1–25

5. US Food and Drug Administration. Daptacel vaccine insert. Available at: www. fda. gov/ BiologicsBloodVac cines/ Vaccines/ ApprovedProducts/ ucm101572. htm. Accessed March 27, 2018

6. US Food and Drug Administration. Infanrix vaccine insert. Available at: www. fda. gov/ BiologicsBloodVac cines/ Vaccines/ ApprovedProducts/ ucm101568. htm. Accessed March 27, 2018

7. US Food and Drug Administration. Pediarix vaccine insert. Available at: www. fda. gov/ BiologicsBloodVac cines/ Vaccines/ ApprovedProducts/ ucm146759. htm. Accessed March 27, 2018

8. US Food and Drug Administration. Pentacel vaccine insert. Available at: www. fda. gov/ BiologicsBloodVac cines/ Vaccines/ ApprovedProducts/ ucm172502. htm. Accessed March 27, 2018

9. US Food and Drug Administration. Kinrix vaccine insert. Available at: www. fda. gov/ BiologicsBloodVac cines/ Vaccines/ ApprovedProducts/ ucm172495. htm. Accessed March 27, 2018

10. US Food and Drug Administration. Quadracel vaccine insert. Available at: https:// www. fda. gov/ downloads/ BiologicsBloodVac cines/ Vaccines/ ApprovedProducts/ UCM439903. pdf. Accessed March 27, 2018

11. Jackson LA, Carste BA, Malais D, Froeschle J. Retrospective populationbased assessment of medically attended injection site reactions, seizures, allergic responses and febrile episodes after acellular pertussis vaccine combined with diphtheria and tetanus toxoids. Pediatr Infect Dis J. 2002;21(8):781–786

12. Huang WT, Gargiullo PM, Broder KR, et al; Vaccine Safety Datalink Team. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics. 2010;126(2):263–269

13. Jackson LA, Yu O, Nelson JC, et al; Vaccine Safety Datalink Team. Injection site and risk of medically attended local reactions to acellular pertussis vaccine. Pediatrics. 2011;127(3). Available at: www. pediatrics. org/ cgi/ content/ full/ 127/ 3/ e581

14. Jackson LA, Peterson D, Nelson JC, et al. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics. 2013;131(2):283–289

15. Andrews N, Stowe J, Wise L, Miller E. Post-licensure comparison of the safety profile of diphtheria/tetanus/ whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom. Vaccine. 2010;28(44):7215–7220

16. Sun Y, Christensen J, Hviid A, et al. Risk of febrile seizures and epilepsy after vaccination with diphtheria, tetanus, acellular pertussis, inactivated poliovirus, and Haemophilus influenzae type B. JAMA. 2012;307(8):823–831

17. Nelson JC, Yu O, Dominguez-Islas CP, et al. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. Am J Epidemiol. 2013;177(2):131–141

18. Daley MF, Yih WK, Glanz JM, et al. Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine. Vaccine. 2014;32(25):3019–3024

19. Hansen J, Timbol J, Lewis N, et al. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine. 2016;34(35):4172–4179

20. Duffy J, Hambidge SJ, Jackson LA, et al; Vaccine Safety Datalink. Febrile seizure risk after vaccination in children one to five months of age. Pediatr Neurol. 2017;76:72–78

21. Moore DL, Le Saux N, Scheifele D, Halperin SA; Members of the Canadian Paediatric Society/Health Canada Immunization Monitoring Program Active. Lack of evidence of encephalopathy related to pertussis vaccine: active surveillance by IMPACT, Canada, 1993-2002. Pediatr Infect Dis J. 2004;23(6):568–571

22. Zangwill KM, Eriksen E, Lee M, et al. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization. Pediatrics. 2008;122(6). Available at: www. pediatrics. org/ cgi/ content/ full/ 122/ 6/ e1179

23. Rosenthal S, Chen R, Hadler S. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med. 1996;150(5):457–460

24. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years’ data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics. 2000;106(4). Available at: www. pediatrics. org/ cgi/ content/ full/ 106/ 4/ e51